Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells
about
Promises and paradoxes of regulatory T cells in inflammatory bowel diseaseImmune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Ipilimumab and its toxicities: a multidisciplinary approachTherapy for metastatic melanoma: the past, present, and future.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitisCancer immunotherapy-induced rheumatic diseases emerge as new clinical entities.Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.Ipilimumab-induced toxicities and the gastroenterologist.Systematic review: colitis associated with anti-CTLA-4 therapy.From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease.Ipilimumab in melanoma.Infliximab for ipilimumab-induced colitis: A series of 13 patients.Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control.Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab.Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.Histopathological and Immunophenotypic Features of Ipilimumab-Associated Colitis Compared to Ulcerative Colitis.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.[The pathology of adverse events with immune checkpoint inhibitors].Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis?
P2860
Q26777557-07351C16-301A-4D14-A12A-B348092A1565Q26785746-9F27ACF1-1AAA-4BC1-82B1-56E60E0DCA52Q33607108-004E1C36-F783-43C9-8B58-C7389DEFBB5DQ33777476-4C3A2E82-2DAF-4313-AFE0-8EC22D01D7F8Q34183225-0B6E6359-5E9F-42AE-92BF-6C799162CF4FQ34577158-98110426-18F6-42F1-8965-CC0AED67E730Q35912366-40AF3231-2DA8-47B7-B9F6-34A257983295Q37308199-32C4A490-EA9B-465D-B0A6-DE821CB03E77Q37312417-31DFB604-6442-42FC-B37C-9E8B7FA4F05DQ37714359-AB02D19C-24E6-4CCC-A0C1-0EB5560806CAQ38166382-258A5330-9827-46ED-A8E8-D7AB8866DC27Q38340321-1956D9A1-EFA6-404A-B104-A5F51667CE7CQ38529051-5B03E035-E0B9-49D1-86D4-1133743E302DQ38619050-7346B649-5267-46A5-81F3-C2E1355EAAD6Q38893697-F558CB24-A621-4070-B431-5597A6701487Q39040949-5C876D50-6299-48F7-9CD1-AECAEE70C2E1Q39449408-1D284EAF-CE5A-4397-97C6-95E537959701Q40959994-C2F2BFE4-8D04-4EA6-B0D8-B552BA46F373Q41826015-49CA76AC-0339-4BCC-9421-E0E0CAA90A28Q43065896-9EDE486E-AB15-4859-992B-95D9964EFF0EQ45026631-392318F9-591C-44D7-AB3C-0CF2604E477BQ47397659-82E145D0-A1F3-4CBE-9523-FE9A5E3CE5C9Q48369113-A9159820-47B0-4931-842D-D96D82FFB8C8Q49719593-5FDBEB45-495F-460D-90CB-A0C0D4E667B7Q50205173-AFB726C2-A376-499A-A86C-30632A863F35Q50653513-6100EE07-0D63-4C05-8202-7180541AD305Q50719439-17305D6F-C472-44D4-9956-FFF733316AC1Q52879625-45959A3F-64A3-40E9-851E-7642C4A5BB17Q53723979-6A2BDF8E-6F7A-4CCE-972B-66EDC13BCD36Q55284597-79762EE0-43EF-4357-AF82-1B6A86EB9210Q56897964-9B392C11-57F3-440F-98C6-2F9C3D0551C0
P2860
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@ast
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@en
type
label
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@ast
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@en
prefLabel
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@ast
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@en
P2093
P2860
P1476
Refractory colitis following a ...... ysis of mucosal FOXP3+ T cells
@en
P2093
Amanda Moklebust
Celestia S Higano
Deborah Chielens
George B McDonald
Gideon Steinbach
James D Lord
John A Thompson
Robert C Hackman
P2860
P2888
P304
P356
10.1007/S10620-009-0839-8
P577
2009-06-09T00:00:00Z
P5875
P6179
1009416899